glp-1 and mental health Prospects of Therapies for Addiction Comorbidities-Quo Vadis?: A Review When the Medication Turns Down

This antioxidant activity may have positive implications for general health and well-being.

NTZ dose-dependently alleviated MTX-induced increase in hepatic MDA, indicating antioxidant properties

The semaglutide plateau is a well-documented phenomenon that typically occurs between months 6 and 12 of treatment

Future research directions include direct comparative trials between various GLP-1 RAs and multi-agonists in MASLD populations to identify optimal therapeutic choices for specific patient subgroups

The GIP component may also contribute to potentially milder gastrointestinal side effects compared to GLP-1-only medications